You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers traced the development of thousands of engineered human lung cancer cells within a mouse model of disease to examine metastasis.
The national lockdown reduced the genetic diversity of the SARS-CoV-2 lineages in the UK, the researchers additionally reported.
An analysis of SARS-CoV-2 genomes from early COVD-19 patients in Scotland shows the virus was introduced there multiple times, typically from continental Europe.
Researchers analyzed viral samples from Boston early in the pandemic to study transmission events, including at a large international conference held there.
In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.
The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.
By sequencing Yersinia pestis isolates from several 14th to 18th century sites, researchers characterized a Second Plague lineage and proposed a reservoir for it.
By combining genome sequence data with phylogenetics and other clues, two teams looked at the SARS-CoV-2 introductions that sparked outbreaks in North America and Europe.
In PNAS this week: genetic diversity of SARS-CoV-2 indicates neutral evolution, portable RT-LAMP method to detect SARS-CoV-2, and more.
In PNAS this week: Zika virus mutation linked to increased transmission, variants associated with inherited hearing loss, and more.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.